{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:11:51Z","timestamp":1784358711456,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005614","name":"BC Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clon.2026.104079","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:58:57Z","timestamp":1770883137000},"page":"104079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial"],"prefix":"10.1016","volume":"52","author":[{"given":"T.","family":"Kunkyab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5636-604X","authenticated-orcid":false,"given":"B.","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1329-3394","authenticated-orcid":false,"given":"J.","family":"Abrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-8093","authenticated-orcid":false,"given":"H.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-9172","authenticated-orcid":false,"given":"A.","family":"Javanmardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3938-3279","authenticated-orcid":false,"given":"M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-340X","authenticated-orcid":false,"given":"F.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-6197","authenticated-orcid":false,"given":"R.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clon.2026.104079_bib1","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: Primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104079_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: An analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"10","key":"10.1016\/j.clon.2026.104079_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/GO.23.00275","article-title":"Second chance for cure: Stereotactic ablative radiotherapy in oligometastatic disease","author":"Salim","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104079_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104079_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10185","key":"10.1016\/j.clon.2026.104079_bib7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clon.2026.104079_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.clon.2026.104079_bib9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12904-024-01548-7","article-title":"A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol","volume":"23","author":"Palma","year":"2024","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.clon.2026.104079_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104079_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clon.2026.104079_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2021.12.001","article-title":"Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy","volume":"114","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2026.104079_bib15","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/j.ijrobp.2024.07.1301","article-title":"Progression free survival prediction for oligometastatic renal cell cancer patients after stereotactic ablative radiation therapy","volume":"120","author":"Tang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2026.104079_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2017.01.003","article-title":"Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease","volume":"123","author":"Tanadini-Lang","year":"2017","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104079_bib17","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.ijrobp.2024.07.2194","article-title":"Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Cancer","volume":"120","author":"Das","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16_suppl","key":"10.1016\/j.clon.2026.104079_bib18","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104079_bib19","article-title":"Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial","author":"Reddy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10422","key":"10.1016\/j.clon.2026.104079_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.clon.2026.104079_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2022.06.094","article-title":"Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.clon.2026.104079_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijrobp.2019.10.038","article-title":"Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: translational correlatives from a mature randomized phase II trial","volume":"106","author":"Tang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1016\/j.clon.2026.104079_bib24","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and limitations of radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1016\/j.clon.2026.104079_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.radonc.2015.02.015","article-title":"CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma","volume":"114","author":"Coroller","year":"2015","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"14","key":"10.1016\/j.clon.2026.104079_bib26","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1088\/0031-9155\/60\/14\/5471","article-title":"A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities","volume":"60","author":"Valli\u00e8res","year":"2015","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1016\/j.clon.2026.104079_bib27","first-page":"449","article-title":"Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features","volume":"28","author":"Sun","year":"2020","journal-title":"J Xray Sci Technol"},{"key":"10.1016\/j.clon.2026.104079_bib28","series-title":"hdclark\/DICOMautomaton: 20220203.1","author":"Clark","year":"2022"},{"key":"10.1016\/j.clon.2026.104079_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imag"},{"key":"10.1016\/j.clon.2026.104079_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109671","article-title":"Repeat stereotactic body radiotherapy for oligometastatic disease","volume":"184","author":"Willmann","year":"2023","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.clon.2026.104079_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","author":"Van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2026.104079_bib32","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acd431","article-title":"Radiomic analysis for early differentiation of lung cancer recurrence from fibrosis in patients treated with lung stereotactic ablative radiotherapy","author":"Kunkyab","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.clon.2026.104079_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuroimage.2017.11.024","article-title":"Harmonization of cortical thickness measurements across scanners and sites","volume":"167","author":"Fortin","year":"2018","journal-title":"Neuroimage"},{"issue":"212","key":"10.1016\/j.clon.2026.104079_bib34","first-page":"1","article-title":"scikit-survival: A library for time-to-event analysis built on top of scikit-learn","volume":"21","author":"P\u00f6lsterl","year":"2020","journal-title":"J Mach Learn Res"},{"key":"10.1016\/j.clon.2026.104079_bib35","first-page":"2825","article-title":"Scikit-learn: Machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"issue":"3","key":"10.1016\/j.clon.2026.104079_bib36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10278-023-00778-0","article-title":"Development and validation of CT-based radiomics signature for overall survival prediction in multi-organ cancer","volume":"36","author":"Le","year":"2023","journal-title":"J Digit Imag"},{"key":"10.1016\/j.clon.2026.104079_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2015.12.369","article-title":"Detection of local cancer recurrence after stereotactic ablative radiation therapy for lung cancer: Physician performance versus radiomic assessment","author":"Mattonen","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-017-0892-y","article-title":"CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy","volume":"12","author":"Li","year":"2017","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104079_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00066-022-02034-w","article-title":"CT radiomic predictors of local relapse after SBRT for lung oligometastases from colorectal cancer: a single institute pilot study","volume":"199","author":"Fodor","year":"2023","journal-title":"Strahlentherapie und Onkol"},{"issue":"1","key":"10.1016\/j.clon.2026.104079_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20931-z","article-title":"Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies","volume":"12","author":"Henry","year":"2022","journal-title":"Sci Rep"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:30:45Z","timestamp":1776155445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0936655526000506"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104079","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104079"}}